Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Join Class Action Suit Seeking Recovery

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from June 22, 2023, to June 24, 2025 [3]. - Allegations include that Sarepta Therapeutics made materially false and misleading statements about ELEVIDYS, which is a gene therapy for Duchenne muscular dystrophy [3]. Specific Allegations - The complaint claims that: - ELEVIDYS posed significant safety risks to patients [3]. - Trial regimes and protocols failed to detect severe side effects [3]. - Adverse events from ELEVIDYS treatment would lead to halting recruitment and dosing in trials, attracting regulatory scrutiny [3]. - The misleading statements resulted in a lack of reasonable basis for positive claims about the therapy [3]. Shareholder Actions - Shareholders are encouraged to register for the class action by August 25, 2025, to potentially become lead plaintiffs [4]. - Registration allows shareholders to receive updates on the case through portfolio monitoring software [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5].